John Treace compensation by year
TREACE MEDICAL CONCEPTS Summary Compensation Table · all 6 fiscal years held| Component | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Salary | $316,153 | $410,141 | $568,219 | $684,384 | $723,410 | $755,353 |
| Bonus | $0 | $0 | $0 | $0 | $0 | $0 |
| Stock awards | $0 | $0 | $648,706 | $5,350,966 | $5,768,814 | $4,635,000 |
| Option awards | $0 | $0 | $1,931,854 | $1,977,589 | $0 | $0 |
| Non-equity incentive | $76,246 | $267,900 | $457,000 | $393,000 | $89,880 | $0 |
| Pension and deferred compensation | $0 | $0 | $0 | $0 | $0 | $0 |
| All other | $0 | $10,104 | $11,470 | $16,696 | $15,056 | $14,837 |
| Total | $392,399 | $688,145 | $3,617,249 | $8,422,635 | $6,597,160 | $5,405,190 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: TREACE MEDICAL CONCEPTS, INC. DEF 14A filed April 6, 2026, accession 0001630627-26-000005, and prior-year filings. Open the filing on EDGAR.
How this page was built: the TREACE MEDICAL CONCEPTS, INC. filed document, accession 0001630627-26-000005. Every figure is read from that document and cited to the page and table it appears in. Filed April 6, 2026.
Equity holdings
unvested awards at FY2025 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| PSU | 225,000 | $551,250 | — |
| RSU | 225,000 | $551,250 | — |
| PSU | 178,325 | $436,896 | — |
| RSU | 133,743 | $327,670 | — |
| RSU | 41,237 | $101,031 | — |
| PSU | 10,000 | $24,500 | — |
| Option | 93,450 | — | $24.07 |
| Option | 60,141 | — | $19.15 |
Per the Outstanding Equity Awards at Fiscal Year-End table in TREACE MEDICAL CONCEPTS, INC.'s FY2025 proxy; value at the fiscal year-end close, as the company printed it.
Insider transactions since the last proxy
14 Form 4 lines since the FY2025 proxy (filed April 6, 2026)current to 2026-11-07 · updated nightly
| Date | Transaction | Plan | Shares | Price | Held after |
|---|---|---|---|---|---|
| 2026-08-24 | Purchase | — | 11,000 | $4.34 | 7,404,383 |
| 2026-08-21 | Purchase | — | 5,000 | $4.35 | 7,393,383 |
| 2026-08-20 | Purchase | — | 39,944 | $4.44 | 7,388,383 |
| 2026-06-11 | Purchase | — | 9,891 | $4.04 | 7,348,439 |
| 2026-06-11 | Purchase | — | 22,887 | $4.04 | 7,376,150 |
| 2026-06-10 | Purchase | — | 14,715 | $4.02 | 7,338,548 |
| 2026-06-10 | Purchase | — | 29,430 | $4.02 | 7,353,263 |
| 2026-06-01 | Purchase | — | 50,000 | $3.56 | 7,323,833 |
The 8 most recent of 14 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →
TREACE MEDICAL CONCEPTS’s named executive officers, FY2025
as the company reported each| Named executive officer | Role | FY2025 total |
|---|---|---|
| John Treace · this page | Chief Executive Officer, Founder and Board Chair | $5,405,190 |
| Mark Hair | Chief Financial Officer | $5,157,046 |
| Sean Scanlan | Chief Innovation Officer | $2,310,894 |
| Scot Elder | Chief Legal & Compliance Officer, Corporate Secretary | $2,123,983 |
| Gaetano Guglielmino | Chief Commercial Officer | $468,536 |
Board service
TREACE MEDICAL CONCEPTS board · FY2023–FY2025How this board is paid
Company policy: TREACE MEDICAL CONCEPTS pays directors a $45,000 cash retainer and $160,000 in RSUs. As stated in TREACE MEDICAL CONCEPTS's FY2025 proxy.
The full TREACE MEDICAL CONCEPTS compensation record
free company briefThis page is one person within TREACE MEDICAL CONCEPTS's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the TREACE MEDICAL CONCEPTS proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order TREACE MEDICAL CONCEPTS's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are TREACE MEDICAL CONCEPTS's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.
Order TMCI
Add the email the receipt and the PDF go to, then press the report you want. Each button opens its own card payment on Stripe.